Immunomodulatory role of histamine H4 receptor in breast cancer.

Animals Antigens, CD19 / immunology Breast Neoplasms / genetics CD4-Positive T-Lymphocytes / immunology Female Forkhead Transcription Factors / immunology Humans Immunomodulation / genetics Killer Cells, Natural / immunology Mice Mice, Knockout Receptors, Histamine H4 / genetics T-Lymphocytes, Regulatory / immunology

Journal

British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635

Informations de publication

Date de publication:
01 2019
Historique:
received: 20 03 2018
accepted: 12 06 2018
revised: 08 06 2018
pubmed: 11 7 2018
medline: 19 9 2019
entrez: 11 7 2018
Statut: ppublish

Résumé

Although the role of histamine H4 receptor (H4R) in immune cells is being extensively investigated, its immunomodulatory function in cancer is completely unknown. This study aimed to investigate the role of H4R in antitumour immunity in a model of triple-negative breast cancer. We evaluated growth parameters, histological characteristics and the composition of tumour, splenic and tumour draining lymph node (TDLN) immune subsets, in a syngeneic model, developed orthotopically with 4T1 cells in H4R knockout (H4R-KO) and wild-type mice. Mice lacking H4R show reduced tumour size and weight, decreased number of lung metastases and percentage of CD4 This is the first report that demonstrates the participation of H4R in antitumour immunity, suggesting that H4R could be a target for cancer treatment.

Sections du résumé

BACKGROUND
Although the role of histamine H4 receptor (H4R) in immune cells is being extensively investigated, its immunomodulatory function in cancer is completely unknown. This study aimed to investigate the role of H4R in antitumour immunity in a model of triple-negative breast cancer.
METHODS
We evaluated growth parameters, histological characteristics and the composition of tumour, splenic and tumour draining lymph node (TDLN) immune subsets, in a syngeneic model, developed orthotopically with 4T1 cells in H4R knockout (H4R-KO) and wild-type mice.
RESULTS
Mice lacking H4R show reduced tumour size and weight, decreased number of lung metastases and percentage of CD4
CONCLUSIONS
This is the first report that demonstrates the participation of H4R in antitumour immunity, suggesting that H4R could be a target for cancer treatment.

Identifiants

DOI: 10.1038/s41416-018-0173-z PMID: 29988113 PMC: PMC6325108
pubmed: 29988113
doi: 10.1038/s41416-018-0173-z
pii: 10.1038/s41416-018-0173-z
pmc: PMC6325108
doi:

Substances chimiques

Antigens, CD19 0
Forkhead Transcription Factors 0
Foxp3 protein, mouse 0
Receptors, Histamine H4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-138

Références

Carcinogenesis. 2013 Apr;34(4):850-7
pubmed: 23241166
Vet Pathol. 2014 Jul;51(4):868-81
pubmed: 24091811
Oncotarget. 2017 Apr 18;8(16):26471-26491
pubmed: 28460440
Cancer Biol Ther. 2006 Nov;5(11):1462-71
pubmed: 17012845
Pharmacol Ther. 2007 Mar;113(3):594-606
pubmed: 17275092
Oncoimmunology. 2012 May 1;1(3):261-262
pubmed: 22737600
Crit Rev Oncog. 2014;19(1-2):57-66
pubmed: 24941373
Br J Pharmacol. 2015 Mar;172(5):1165-78
pubmed: 25363289
Commun Integr Biol. 2010 Nov;3(6):508-12
pubmed: 21331226
J Immunol. 2007 Jun 15;178(12):8081-9
pubmed: 17548646
Clin Med Insights Oncol. 2016 Apr 05;10(Suppl 1):31-9
pubmed: 27081325
Immunotherapy. 2011 Oct;3(10):1143-66
pubmed: 21995569
Breast Cancer Res Treat. 2012 May;133(1):11-21
pubmed: 22057973
J Allergy Clin Immunol. 2009 Mar;123(3):619-25
pubmed: 19281909
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Front Biosci (Elite Ed). 2011 Jun 01;3:1042-60
pubmed: 21622113
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Int Arch Allergy Immunol. 2015;166(3):225-30
pubmed: 25924652
Immunity. 2007 Oct;27(4):635-46
pubmed: 17919943
J Pharmacol Exp Ther. 2003 Jun;305(3):1212-21
pubmed: 12626656
Front Biosci (Schol Ed). 2015 Jun 01;7:1-9
pubmed: 25961682
Cancer Biol Ther. 2008 Jan;7(1):28-35
pubmed: 17932461
Mol Pharmacol. 2001 Mar;59(3):434-41
pubmed: 11179436
Immunobiology. 2015 Mar;220(3):341-9
pubmed: 25457414
Br J Pharmacol. 2004 May;142(1):161-71
pubmed: 15131002
Eur J Cancer. 2014 Apr;50(6):1195-206
pubmed: 24447834
J Mol Med (Berl). 2016 Apr;94(4):417-29
pubmed: 26564151
Oncoimmunology. 2012 Oct 1;1(7):1186-1188
pubmed: 23170274
Ther Adv Med Oncol. 2013 May;5(3):169-81
pubmed: 23634195
J Biol Chem. 2000 Nov 24;275(47):36781-6
pubmed: 10973974
Cancer Immunol Immunother. 2006 Jun;55(6):699-707
pubmed: 16047144
Cancer Discov. 2011 Jun;1(1):54-67
pubmed: 22039576
Br J Pharmacol. 2009 May;157(1):24-33
pubmed: 19309354
Curr Allergy Asthma Rep. 2008 Mar;8(1):21-7
pubmed: 18377770
J Dermatol Sci. 2013 Dec;72(3):252-62
pubmed: 23999004
J Immunol. 2015 May 15;194(10):5014-21
pubmed: 25870245
BMC Cancer. 2008 Aug 09;8:228
pubmed: 18691423
J Pharmacol Sci. 2007 Sep;105(1):66-73
pubmed: 17895589
Biochem Pharmacol. 2016 Mar 1;103:74-84
pubmed: 26774453
J Cell Physiol. 2014 Feb;229(2):139-47
pubmed: 23893766
J Immunol. 2005 May 1;174(9):5224-32
pubmed: 15843518
J Immunol. 2006 Jun 1;176(11):7062-70
pubmed: 16709868
Br J Pharmacol. 2010 Oct;161(4):755-67
pubmed: 20636392
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Eur J Pharmacol. 2005 Oct 17;522(1-3):130-8
pubmed: 16213481
Immunobiology. 2013 Nov;218(11):1402-10
pubmed: 23891329
Br J Pharmacol. 2013 Sep;170(1):188-99
pubmed: 23425150
J Pharmacol Exp Ther. 2002 Oct;303(1):300-7
pubmed: 12235264
Int J Cancer. 2013 May 1;132(9):1971-6
pubmed: 22858832
Breast Cancer Res. 2007;9(4):212
pubmed: 17705880
J Pharmacol Exp Ther. 2004 Apr;309(1):404-13
pubmed: 14722321
J Immunol. 2007 Dec 1;179(11):7907-15
pubmed: 18025238
Immunity. 2013 Nov 14;39(5):806-18
pubmed: 24238338
Exp Mol Pathol. 2007 Feb;82(1):12-24
pubmed: 16919266
Front Pharmacol. 2015 Mar 31;6:65
pubmed: 25873897
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
Eur J Pharmacol. 2007 Jun 1;563(1-3):240-4
pubmed: 17382315
Allergy. 2016 Feb;71(2):189-97
pubmed: 26440543
Tumour Biol. 2017 Apr;39(4):1010428317695023
pubmed: 28378631
J Transl Med. 2015 Jun 04;13:180
pubmed: 26040463
Biomed Pharmacother. 2001 Mar;55(2):111-6
pubmed: 11293814
J Immunol. 2012 Jan 15;188(2):541-7
pubmed: 22147765
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
J Immunother Cancer. 2017 Oct 17;5(1):79
pubmed: 29037250
Mol Pharmacol. 2001 Mar;59(3):420-6
pubmed: 11179434
J Dermatol Sci. 2016 Aug;83(2):106-15
pubmed: 27155791
Eur J Pharmacol. 2011 Jan 25;651(1-3):197-204
pubmed: 21093429

Auteurs

Helena A Sterle (HA)

Neuroimmunomodulation and Molecular Oncology Division, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.

Melisa B Nicoud (MB)

Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.

Noelia A Massari (NA)

Immunology Department, School of Natural Sciences, National University of Patagonia San Juan Bosco, Chubut, Argentina.

Mónica A Táquez Delgado (MA)

Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.

María V Herrero Ducloux (MV)

Pathology Department, School of Natural Sciences, National University of Patagonia San Juan Bosco, Chubut, Argentina.

Graciela A Cremaschi (GA)

Neuroimmunomodulation and Molecular Oncology Division, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.

Vanina A Medina (VA)

Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina. vmedina@ffyb.uba.ar.
Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina. vmedina@ffyb.uba.ar.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes B › Antigènes CD19 › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif hélice ailée › Facteurs de transcription Forkhead › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Cellules tueuses naturelles › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs histaminergiques › Récepteur histaminergique H4 › Immunomodulatory role of histamine H4 receptor...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T régulateurs › Immunomodulatory role of histamine H4 receptor...